Navigation mit Access Keys

Changing where and how we look for phages: combining hidden genomes with mass isolation to expand the therapeutic phage landscape

Therapeutic phage discovery has usually started with environmental sampling and plaque-based isolation. In contrast, bacterial genome datasets have mainly been searched for temperate prophages, with the assumption that lytic phages are unlikely to be found there. However, phage biology is not always this simple. States such as pseudolysogeny and carrier-state infection suggest that lytic phages may sometimes remain associated with bacterial cells, meaning that bacterial genome assemblies could contain a large, underexplored source of therapeutically relevant phage diversity. Here, we asked whether changing where and how we look for phages could expand the therapeutic phage landscape, in other words the number of phages we can access to characterise. We combined large-scale bacterial genome mining with mass phage isolation at the Becky Mayer Centre for Phage Research. Using the machine-learning framework Phager, trained on PhageCloud and NCBI phage genomes, we analysed more than 230 million contigs from 3.6 million bacterial and archaeal assemblies. After prediction and quality filtering, this identified 119,510 putative lytic phage genomes, expanding known lytic phage diversity by approximately fivefold. Alongside this, we isolated, plaque-purified and sequenced 1,012 lytic Escherichia coli phages from zoo animal faeces and sewage, using more than 25 clinical E. coli strains plus MG1655 as isolation hosts. This large-scale isolation was supported by Plaque-2-seq, a rapid and cost-effective workflow for generating whole-genome data directly from plaques. Comparative genomic analysis showed that many BAPS-derived E. coli phages cluster closely with isolated BMCPR phages and with known therapeutic or experimentally characterised phages, including T4-, T5- and T7-like groups. This shows that bacterial assemblies contain genomic relatives of real, plaque-forming phages. Together, these data suggest that changing where and how we look and that combining hidden phage genomes in bacterial assemblies with large-scale recovery of real plaques can open new routes for therapeutic phage discovery. Carrying out genome mining alongside mass isolation gives us recoverable phages for phenotypic testing and a much richer genomic and host context which will provide a scalable route to identify and prioritise new candidates for therapeutic development.